Symphony Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/ne45okbvsrxv6hk5jh7cpnu5.pdf

Key Takeaways


Margin Drivers & Cost Structure

Shah: "what we have earned from IMPCO Mexico, that we lost in Australia. So, ultimately, both put together has become a zero-sum game."

Australia Restructuring


Domestic Demand & Channel Dynamics


Product & Market Expansion


International Markets & Geopolitical Exposure


Guidance & Commitments

CommitmentSpecificsTimeline
Australia CODB reductionEnd FY23-24 below AUD 0.7 crore (vs ~AUD 1.5 crore pre-acquisition); further reduction next yearFY23-24 exit / FY24-25
Australia transition completionTransition largely complete; full benefit and effect visibleEnd of current financial year / next year (2024-2025)
Channel inventory normalizationBring to normal levels, subject to weatherBy end of coming season
No short-term or medium-term guidanceNew IR policy: focus on actual performance and deliveryEffective immediately
Shah: "in line with most of the consumer durable and consumer facing companies, we are not going to issue any guidance, whether short term or medium term. Let us more focus on actual performance and delivery."

Key Metrics

MetricQ2 FY24
Revenue (consolidated)₹275 cr, marginally higher YoY
Revenue (standalone)₹196 cr, in line with Q2 last year; domestic sales ₹191 cr
EBITDA (standalone)₹53 cr, up 13% YoY
EBITDA margin (standalone)26.8%, up in excess of 5 ppt YoY from 21.6%
PAT (standalone)₹50 cr, up 11% YoY
PAT margin (standalone)25.4%, up 470 bps YoY, including treasury income
EBITDA (consolidated)₹42 cr, up 16% YoY
EBITDA margin (consolidated)15.5%, up 210 bps YoY
PAT (consolidated)₹35 cr, up 10% YoY
PAT margin (consolidated)12.7%
ROCE (standalone core business)296%
ROCE (consolidated core business)37%
Return on net worth (standalone)21%
Treasury (standalone)₹589 cr, excluding equity investment and loans to subsidiaries
Capital employed (standalone, TTM monthly avg)₹55 cr, marginally lower YoY
Market share (organized sector)~50%
Alternate channel sales share>30% of annual sales, vs ~10% pre-COVID
Climate Technologies Australia H1 revenue₹91 cr, vs ₹115 cr in H1 last year
Climate Technologies Australia H1 EBITDAnegative ₹14 cr, vs negative ₹11 cr in H1 last year
IMPCO Mexico H1 revenue₹107 cr, vs ₹69 cr in H1 last year
IMPCO Mexico H1 EBITDApositive ₹18 cr, vs ₹7 cr in H1 last year
GSK China H1 revenue₹23 cr, vs ₹19 cr in H1 last year
GSK China H1 EBITDApositive ₹3 cr, vs ₹1 cr in H1 last year
Second interim dividend₹2 per share, amounting to ₹14 cr
CODB reduction Australia (FY23-24)less than AUD 0.7 cr, down from ~AUD 1.5 cr pre-acquisition